Edgewise Therapeutics, Inc.
NASDAQ•EWTX
CEO: Dr. Peter A. Thompson FACP, M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2021-03-26
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
連絡先情報
時価総額
$3.18B
PER (TTM)
-20.2
19.5
配当利回り
--
52週高値
$31.29
52週安値
$10.60
52週レンジ
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025
財務ダッシュボード
Q3 2025 データ
売上高
$0.00+0.00%
直近4四半期の推移
EPS
-$0.39+8.33%
直近4四半期の推移
フリーCF
-$34.87M+24.99%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Strong Asset Position Growth Total assets reached $583.5M, driven by $517.3M in marketable securities available for sale as of September 30, 2025.
Research Spending Ramps Up Nine-month R&D expenses rose $17.2M to $107.8M, supporting clinical advancement of lead candidates like sevasemten and EDG-7500.
Capital Inflows Support Operations Financing activities provided $192.1M net cash over nine months, funding operations amid ongoing net losses for drug development.
Common Shares Outstanding Increased Outstanding common shares grew to 105.9M shares following registered direct offerings completed in January 2024 and April 2025.
リスク要因
Increased Operating Cash Usage Net cash used in operating activities increased to $(105.2M) for nine months, necessitating continued reliance on capital raises.
Lead Candidate Development Uncertainty Success hinges on timely clinical completion and regulatory approval for sevasemten and EDG-7500; failure harms the entire business outlook.
Intense Market Competition Noted Significant competition exists from established therapies and other pipeline products in Duchenne and HCM, potentially limiting market acceptance.
Operating Expenses Rising Sharply Total operating expenses increased $22.1M over nine months, driven by R&D advancement costs and increased personnel-related expenses.
見通し
Cash Funds Next Twelve Months Existing cash, cash equivalents, and marketable securities of $563.3M are expected to fund operations for at least the next 12 months.
Advance Key Clinical Stage Programs Expect substantial spending to progress sevasemten, EDG-7500, and EDG-15400 through the remainder of their respective clinical development phases.
Substantial Future Capital Required Substantial additional funding will be required to complete development and commercialization efforts for product candidates if current cash runs low.
G&A Expenses Anticipated Increase General and administrative expenses are expected to increase as headcount grows to support continued research and development programs.
同業比較
売上高 (TTM)
NVAX$1.06B
HRMY$825.94M
$316.64M
粗利益率 (最新四半期)
475.5%
VRDN100.0%
ABCL100.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| EWTX | $3.18B | -20.2 | -30.9% | 0.7% |
| VERA | $3.00B | -10.9 | -50.9% | 14.9% |
| WVE | $2.30B | -17.3 | -75.6% | 8.2% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年3月2日
EPS:-$0.43
|売上高:-
財務レポート
財務データ
ニュース
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年11月6日|売上高: $0.00+0.0%|EPS: $-0.39+8.3%不明Form 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月7日|売上高: $0.00+0.0%|EPS: $-0.34+0.0%不明Form 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年5月8日|売上高: $0.00+0.0%|EPS: $-0.43+30.3%不明Form 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年3月3日|売上高: $0.00+0.0%|EPS: $-1.45+7.6%不明Form 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年11月7日|売上高: $0.00+0.0%|EPS: $-0.36-12.2%不明Form 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月8日|売上高: $0.00+0.0%|EPS: $-0.34+0.0%不明Form 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月9日|売上高: $0.00+0.0%|EPS: $-0.33+6.5%不明Form 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月22日|売上高: $0.00+0.0%|EPS: $-1.57-24.6%不明